Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

Published:2015-10 Issue:1 Volume:110 Page:82-90
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Haering Hans-Ulrich,Merker Ludwig,Christiansen Anita Vedel,Roux Flavien,Salsali Afshin,Kim Gabriel,Meinicke Thomas,Woerle Hans J.,Broedl Uli C.

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference21 articles.

1. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

2. Banting lecture from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus;DeFronzo;Diabetes,2009

3. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen;Riedel;Am J Manage Care,2007

4. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012

5. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes;Heise;Diabetes Obes Metab,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians;Annals of Internal Medicine;2024-05

2. Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial;Beni-Suef University Journal of Basic and Applied Sciences;2023-11-08

3. Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial;Diabetes Research and Clinical Practice;2023-09

4. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

5. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-06-13